{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:55:56Z","timestamp":1787327756629,"version":"build-2736575974"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011852","name":"Paracelsus Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011852","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Late-stage Parkinson\u2019s disease (LSPD) presents with disabling motor and non-motor symptoms, the latter becoming dominant in the late stage. There is limited information on LSPD. This study aimed to identify common symptoms and common drug treatments of LSPD. We conducted an online survey of physicians treating patients with Parkinson\u2019s disease in specialized palliative care across Austria, Germany and Switzerland, followed by a two-round Delphi survey involving movement disorder specialists. Consensus was defined as\u2009\u2265\u200975% agreement. 118 participants of 1252 contacted institutions completed the survey. In the Delphi process, eight experts out of 19 participated. Most frequently reported symptoms were dysphagia (94%), rigidity (78%), speech disorder (70%), bradykinesia (61%), dementia (74%) and constipation (64%). Most frequently used medications for motor symptom control at admission to palliative care were levodopa (96%) and rotigotine (48%). Similarly, levodopa (64%) and rotigotine (49%) were most frequently reported to be prescribed until the end of palliative care. Delphi experts agreed on the importance of oral and intestinal levodopa as well as rotigotine for the palliative care phase. Levodopa therapy should be maintained until end of life. Regarding non-motor symptom control, Delphi panelists concluded that laxatives, antipsychotics and medications for hypersalivation should be administered until end of life. Macrogol (70%) and sodium picosulfate (71%) were the most favored laxatives. Among antipsychotics quetiapine was most recommended for psychosis (76%) and delirium (59%) management. However, Delphi panelists agreed on clozapine for psychosis management and quetiapine for delirium management. For hypersalivation, consensus was reached on botulinum toxin injection. harmacological treatment of LSPD should be based on a symptom-oriented and stage-based approach. Therapy encompasses levodopa and non-dopaminergic treatments for non-motor symptom control.<\/jats:p>","DOI":"10.1007\/s00702-026-03255-4","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:51:03Z","timestamp":1787323863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Symptom prevalence and pharmacological management of late-stage Parkinson\u2019s disease (LSPD): a cross-sectional, multinational survey"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2434-5667","authenticated-orcid":false,"given":"Christine","family":"Pallauf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4980-0300","authenticated-orcid":false,"given":"Christiane","family":"Weck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Brandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-0821","authenticated-orcid":false,"given":"Stefan","family":"Lorenzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"12","key":"3255_CR1","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, Onuk K, Odin PLA (2018) Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Curr Med Res Opin 34(12):2063\u20132073. https:\/\/doi.org\/10.1080\/03007995.2018.1502165","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"3255_CR2","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1007\/s12325-021-01747-1","volume":"38","author":"A Antonini","year":"2021","unstructured":"Antonini A, Odin P, Pahwa R, Aldred J, Alobaidi A, Jalundhwala YJ, Kukreja P, Bergmann L, Inguva S, Bao Y, Chaudhuri KR (2021) The long-term impact of Levodopa\/Carbidopa intestinal gel on \u2019off\u2019-time in patients with advanced Parkinson\u2019s disease: a systematic review. Adv Ther 38(6):2854\u20132890. https:\/\/doi.org\/10.1007\/s12325-021-01747-1","journal-title":"Adv Ther"},{"issue":"4","key":"3255_CR3","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s13311-020-00889-4","volume":"17","author":"SD Aradi","year":"2020","unstructured":"Aradi SD, Hauser RA (2020) Medical management and prevention of motor complications in Parkinson\u2019s disease. Neurotherapeutics 17(4):1339\u20131365. https:\/\/doi.org\/10.1007\/s13311-020-00889-4","journal-title":"Neurotherapeutics"},{"issue":"6","key":"3255_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1368-5031.2006.00967.x","volume":"60","author":"C Ballard","year":"2006","unstructured":"Ballard C, Lane R, Barone P, Ferrara R, Tekin S (2006) Cardiac safety of rivastigmine in Lewy body and Parkinson\u2019s disease dementias. Int J Clin Pract 60(6):639\u2013645. https:\/\/doi.org\/10.1111\/j.1368-5031.2006.00967.x","journal-title":"Int J Clin Pract"},{"issue":"1","key":"3255_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-018-1184-3","volume":"18","author":"M Balzer-Geldsetzer","year":"2018","unstructured":"Balzer-Geldsetzer M, Ferreira J, Odin P, Bloem BR, Meissner WG, Lorenzl S, Wittenberg M, Dodel R, Schrag A (2018) Study protocol: care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. BMC Neurol 18(1):185. https:\/\/doi.org\/10.1186\/s12883-018-1184-3","journal-title":"BMC Neurol"},{"issue":"5","key":"3255_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/14740338.2025.2467813","volume":"24","author":"LL Borek","year":"2025","unstructured":"Borek LL, Friedman JH (2025) Treating psychosis in people with Parkinson\u2019s disease. Expert Opin Drug Saf 24(5):513\u2013518. https:\/\/doi.org\/10.1080\/14740338.2025.2467813","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"3255_CR7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/s0006-3223(02)01392-6","volume":"52","author":"A Breier","year":"2002","unstructured":"Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH (2002) Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson\u2019s disease. Biol Psychiatry 52(5):438\u2013445. https:\/\/doi.org\/10.1016\/s0006-3223(02)01392-6","journal-title":"Biol Psychiatry"},{"issue":"11","key":"3255_CR8","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/mds.21077","volume":"21","author":"D Burn","year":"2006","unstructured":"Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R (2006) Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson\u2019s disease. Mov Disord 21(11):1899\u20131907. https:\/\/doi.org\/10.1002\/mds.21077","journal-title":"Mov Disord"},{"key":"3255_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030238","author":"M Carli","year":"2021","unstructured":"Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, Aringhieri S, Fasciani I, Annibale P, Maggio R, Scarselli M (2021) Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph14030238","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"3255_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrneurol.2012.126","volume":"8","author":"M Coelho","year":"2012","unstructured":"Coelho M, Ferreira JJ (2012) Late-stage Parkinson disease. Nat Rev Neurol 8(8):435\u2013442. https:\/\/doi.org\/10.1038\/nrneurol.2012.126","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"3255_CR11","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s00415-010-5566-8","volume":"257","author":"M Coelho","year":"2010","unstructured":"Coelho M, Marti MJ, Tolosa E, Ferreira JJ, Valldeoriola F, Rosa M, Sampaio C (2010) Late-stage Parkinson\u2019s disease: the Barcelona and Lisbon cohort. J Neurol 257(9):1524\u20131532. https:\/\/doi.org\/10.1007\/s00415-010-5566-8","journal-title":"J Neurol"},{"issue":"2","key":"3255_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/ene.12567","volume":"22","author":"M Coelho","year":"2015","unstructured":"Coelho M, Marti MJ, Sampaio C, Ferreira JJ, Valldeoriola F, Rosa MM, Tolosa E (2015) Dementia and severity of parkinsonism determines the handicap of patients in late-stage Parkinson\u2019s disease: the Barcelona-Lisbon cohort. Eur J Neurol 22(2):305\u2013312. https:\/\/doi.org\/10.1111\/ene.12567","journal-title":"Eur J Neurol"},{"issue":"8","key":"3255_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/jamaneurol.2023.1835","volume":"80","author":"E d\u2019Angremont","year":"2023","unstructured":"d\u2019Angremont E, Begemann MJH, van Laar T, Sommer IEC (2023) Cholinesterase inhibitors for treatment of psychotic symptoms in alzheimer disease and parkinson disease: a meta-analysis. JAMA Neurol 80(8):813\u2013823. https:\/\/doi.org\/10.1001\/jamaneurol.2023.1835","journal-title":"JAMA Neurol"},{"issue":"5","key":"3255_CR14","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/mds.30162","volume":"40","author":"RMA de Bie","year":"2025","unstructured":"de Bie RMA, Katzenschlager R, Swinnen B, Peball M, Lim SY, Mestre TA, Perez Lloret S, Coelho M, Aquino C, Tan AH, Bruno V, Dijk JM, Heim B, Lin CH, Kauppila LA, Litvan I, Spijker R, Seppi K, Costa J, Silverdale MA (2025) Update on treatments for parkinson\u2019s disease motor fluctuations\u2014an International Parkinson and Movement Disorder Society evidence-based medicine review. Mov Disord 40(5):776\u2013794. https:\/\/doi.org\/10.1002\/mds.30162","journal-title":"Mov Disord"},{"issue":"3","key":"3255_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1300\/j354v21n03_05","volume":"21","author":"L De Lima","year":"2007","unstructured":"De Lima L, Doyle D (2007) The International Association for Hospice and Palliative Care list of essential medicines for palliative care. J Pain Palliat Care Pharmacother 21(3):29\u201336. https:\/\/doi.org\/10.1300\/j354v21n03_05","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"15","key":"3255_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3238\/arztebl.m2025.0083","volume":"122","author":"M Djukic","year":"2025","unstructured":"Djukic M, Yoshida-Stiksrud E, Nau R (2025) The treatment of older patients with Parkinson\u2019s disease. Dtsch Arztebl Int 122(15):412\u2013418. https:\/\/doi.org\/10.3238\/arztebl.m2025.0083","journal-title":"Dtsch Arztebl Int"},{"key":"3255_CR125","doi-asserted-by":"publisher","unstructured":"Eichhorn TE, Oertel WH (2001) Macrogol 3350\/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 16 6):1176\u20131177. https:\/\/doi.org\/10.1002\/mds.1211","DOI":"10.1002\/mds.1211"},{"issue":"1","key":"3255_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ana.25923","volume":"89","author":"AJ Espay","year":"2021","unstructured":"Espay AJ, Marsili L, Mahajan A, Sturchio A, Pathan R, Pilotto A, Elango DS, Pezous N, Masellis M, Gomez-Mancilla B (2021) Rivastigmine in Parkinson\u2019s disease dementia with orthostatic hypotension. Ann Neurol 89(1):91\u201398. https:\/\/doi.org\/10.1002\/ana.25923","journal-title":"Ann Neurol"},{"key":"3255_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.parkreldis.2016.02.021","volume":"26","author":"M Fabbri","year":"2016","unstructured":"Fabbri M, Coelho M, Abreu D, Guedes LC, Rosa MM, Costa N, Antonini A, Ferreira JJ (2016) Do patients with late-stage Parkinson\u2019s disease still respond to levodopa? Parkinsonism Relat Disord 26:10\u201316. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.02.021","journal-title":"Parkinsonism Relat Disord"},{"key":"3255_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.parkreldis.2017.02.007","volume":"39","author":"M Fabbri","year":"2017","unstructured":"Fabbri M, Coelho M, Guedes LC, Chendo I, Sousa C, Rosa MM, Abreu D, Costa N, Godinho C, Antonini A, Ferreira JJ (2017) Response of non-motor symptoms to levodopa in late-stage Parkinson\u2019s disease: results of a levodopa challenge test. Parkinsonism Relat Disord 39:37\u201343. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.02.007","journal-title":"Parkinsonism Relat Disord"},{"key":"3255_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.parkreldis.2019.02.043","volume":"64","author":"M Fabbri","year":"2019","unstructured":"Fabbri M, Coelho M, Abreu D, Guedes LC, Rosa MM, Godinho C, Cardoso R, Guimaraes I, Antonini A, Zibetti M, Lopiano L, Ferreira JJ (2019) Dysphagia predicts poor outcome in late-stage Parkinson\u2019s disease. Parkinsonism Relat Disord 64:73\u201381. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.02.043","journal-title":"Parkinsonism Relat Disord"},{"issue":"s1","key":"3255_CR21","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.3233\/jpd-202096","volume":"10","author":"M Fabbri","year":"2020","unstructured":"Fabbri M, Kauppila LA, Ferreira JJ, Rascol O (2020) Challenges and perspectives in the management of late-stage Parkinson\u2019s disease. J Parkinsons Dis 10(s1):S75-s83. https:\/\/doi.org\/10.3233\/jpd-202096","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"3255_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","volume":"20","author":"JJ Ferreira","year":"2013","unstructured":"Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Sch\u00fcpbach M, Tolosa E, Trenkwalder C, Oertel WH (2013) Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson\u2019s disease. Eur J Neurol 20(1):5\u201315. https:\/\/doi.org\/10.1111\/j.1468-1331.2012.03866.x","journal-title":"Eur J Neurol"},{"key":"3255_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00621","volume":"10","author":"G Frazzitta","year":"2019","unstructured":"Frazzitta G, Ferrazzoli D, Folini A, Palamara G, Maestri R (2019) Severe constipation in Parkinson\u2019s disease and in Parkinsonisms: prevalence and affecting factors. Front Neurol 10:621. https:\/\/doi.org\/10.3389\/fneur.2019.00621","journal-title":"Front Neurol"},{"issue":"1","key":"3255_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12883-018-1034-3","volume":"18","author":"J Gan","year":"2018","unstructured":"Gan J, Wan Y, Shi J, Zhou M, Lou Z, Liu Z (2018) A survey of subjective constipation in Parkinson\u2019s disease patients in Shanghai and literature review. BMC Neurol 18(1):29. https:\/\/doi.org\/10.1186\/s12883-018-1034-3","journal-title":"BMC Neurol"},{"issue":"1","key":"3255_CR26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1044\/2021_ajslp-21-00145","volume":"31","author":"P Gandhi","year":"2022","unstructured":"Gandhi P, Steele CM (2022) Effectiveness of interventions for dysphagia in Parkinson disease: a systematic review. Am J Speech Lang Pathol 31(1):463\u2013485. https:\/\/doi.org\/10.1044\/2021_ajslp-21-00145","journal-title":"Am J Speech Lang Pathol"},{"issue":"15","key":"3255_CR27","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, LaPelle N (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170. https:\/\/doi.org\/10.1002\/mds.22340","journal-title":"Mov Disord"},{"issue":"2","key":"3255_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5152\/npa.2016.12758","volume":"54","author":"E G\u00f6k\u00e7al","year":"2017","unstructured":"G\u00f6k\u00e7al E, G\u00fcr VE, Selvitop R, Babacan Yildiz G, Asil T (2017) Motor and non-motor symptoms in Parkinson\u2019s Disease: effects on quality of life. Noro Psikiyatr Ars 54(2):143\u2013148. https:\/\/doi.org\/10.5152\/npa.2016.12758","journal-title":"Noro Psikiyatr Ars"},{"issue":"36","key":"3255_CR29","doi-asserted-by":"publisher","first-page":"E989","DOI":"10.1503\/cmaj.181504","volume":"191","author":"D Grimes","year":"2019","unstructured":"Grimes D, Fitzpatrick M, Gordon J, Miyasaki J, Fon EA, Schlossmacher M, Suchowersky O, Rajput A, Lafontaine AL, Mestre T, Appel-Cresswell S, Kalia SK, Schoffer K, Zurowski M, Postuma RB, Udow S, Fox S, Barbeau P, Hutton B (2019) Canadian guideline for Parkinson disease. CMAJ 191(36):E989-e1004. https:\/\/doi.org\/10.1503\/cmaj.181504","journal-title":"CMAJ"},{"key":"3255_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419843458","volume":"12","author":"M Gubbiotti","year":"2019","unstructured":"Gubbiotti M, Conte A, Di Stasi SM, Tambasco N, Giannantoni A (2019) Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson\u2019s disease: a pilot study. Ther Adv Neurol Disord 12:1756286419843458. https:\/\/doi.org\/10.1177\/1756286419843458","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"3255_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.23473","volume":"26","author":"A Guidubaldi","year":"2011","unstructured":"Guidubaldi A, Fasano A, Ialongo T, Piano C, Pompili M, Mascian\u00e0 R, Siciliani L, Sabatelli M, Bentivoglio AR (2011) Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson\u2019s disease. Mov Disord 26(2):313\u2013319. https:\/\/doi.org\/10.1002\/mds.23473","journal-title":"Mov Disord"},{"issue":"11","key":"3255_CR32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","volume":"21","author":"PM Haddad","year":"2007","unstructured":"Haddad PM, Sharma SG (2007) Adverse effects of atypical antipsychotics. CNS Drugs 21(11):911\u2013936. https:\/\/doi.org\/10.2165\/00023210-200721110-00004","journal-title":"CNS Drugs"},{"key":"3255_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020144","author":"MN Han","year":"2022","unstructured":"Han MN, Finkelstein DI, McQuade RM, Diwakarla S (2022) Gastrointestinal dysfunction in Parkinson\u2019s disease: current and potential therapeutics. J Pers Med. https:\/\/doi.org\/10.3390\/jpm12020144","journal-title":"J Pers Med"},{"key":"3255_CR34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.parkreldis.2016.09.001","volume":"32","author":"A Hand","year":"2016","unstructured":"Hand A, Gray WK, Oates LL, Woolford M, Todd A, Bale E, Jones C, Wood BH, Walker RW (2016) Medication use in people with late stage Parkinson\u2019s disease and parkinsonism living at home and in institutional care in north-east England: a balance of symptoms and side-effects? Parkinsonism Relat Disord 32:120\u2013123. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.09.001","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"3255_CR35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov Disord 23(6):837\u2013844. https:\/\/doi.org\/10.1002\/mds.21956","journal-title":"Mov Disord"},{"key":"3255_CR36","unstructured":"H\u00f6glinger G, Trenkwalder C (2023) Parkinson-Krankheit, S2k-Leitlinie. vol Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.)"},{"issue":"1","key":"3255_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s42466-024-00325-4","volume":"6","author":"G H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger G, Trenkwalder C, GPSG Committee (2024) Diagnosis and treatment of Parkinson\u00b4s disease (guideline of the German Society for Neurology). Neurol Res Pract 6(1):30. https:\/\/doi.org\/10.1186\/s42466-024-00325-4","journal-title":"Neurol Res Pract"},{"issue":"3","key":"3255_CR38","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3233\/jpd-202033","volume":"10","author":"A Hommel","year":"2020","unstructured":"Hommel A, Meinders MJ, Weerkamp NJ, Richinger C, Schmotz C, Lorenzl S, Dodel R, Coelho M, Ferreira JJ, Tison F, Boraud T, Meissner WG, Rosqvist K, Timpka J, Odin P, Wittenberg M, Bloem BR, Koopmans RT, Schragand A (2020a) Optimizing treatment in undertreated late-stage Parkinsonism: a pragmatic randomized trial. J Parkinsons Dis 10(3):1171\u20131184. https:\/\/doi.org\/10.3233\/jpd-202033","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"3255_CR39","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3233\/JPD-202033","volume":"10","author":"ALAJ Hommel","year":"2020","unstructured":"Hommel ALAJ, Meinders MJ, Weerkamp NJ, Richinger C, Schmotz C, Lorenzl S, Dodel R, Coelho M, Ferreira JJ, Tison F, Boraud T, Meissner WG, Rosqvist K, Timpka J, Odin P, Wittenberg M, Bloem BR, Koopmans RT, Schragand A, consortium C (2020b) Optimizing treatment in undertreated late-stage Parkinsonism: a pragmatic randomized trial. J Parkinsons Dis 10(3):1171\u20131184. https:\/\/doi.org\/10.3233\/JPD-202033","journal-title":"J Parkinsons Dis"},{"issue":"10","key":"3255_CR40","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/mds.22596","volume":"24","author":"H Honig","year":"2009","unstructured":"Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR (2009) Intrajejunal levodopa infusion in Parkinson\u2019s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24(10):1468\u20131474. https:\/\/doi.org\/10.1002\/mds.22596","journal-title":"Mov Disord"},{"issue":"2","key":"3255_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40266-024-01170-5","volume":"42","author":"RL Hui","year":"2025","unstructured":"Hui RL, Lee AL, Lee EA, Lee RS, Niu F (2025) Safety of low-dose Quetiapine for insomnia in older adults. Drugs Aging 42(2):127\u2013133. https:\/\/doi.org\/10.1007\/s40266-024-01170-5","journal-title":"Drugs Aging"},{"issue":"12","key":"3255_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243437","volume":"15","author":"E Iqbal","year":"2020","unstructured":"Iqbal E, Govind R, Romero A, Dzahini O, Broadbent M, Stewart R, Smith T, Kim CH, Werbeloff N, MacCabe JH, Dobson RJB, Ibrahim ZM (2020) The side effect profile of Clozapine in real world data of three large mental health hospitals. PLoS ONE 15(12):e0243437. https:\/\/doi.org\/10.1371\/journal.pone.0243437","journal-title":"PLoS ONE"},{"key":"3255_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12110691","author":"J Isaacson","year":"2020","unstructured":"Isaacson J, Patel S, Torres-Yaghi Y, Pag\u00e1n F (2020) Sialorrhea in Parkinson\u2019s disease. Toxins (Basel). https:\/\/doi.org\/10.3390\/toxins12110691","journal-title":"Toxins (Basel)"},{"issue":"4","key":"3255_CR44","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/01.wnf.0000174932.82134.e2","volume":"28","author":"C Juri","year":"2005","unstructured":"Juri C, Chan\u00e1 P, Tapia J, Kunstmann C, Parrao T (2005) Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clin Neuropharmacol 28(4):185\u2013187. https:\/\/doi.org\/10.1097\/01.wnf.0000174932.82134.e2","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"3255_CR45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40266-019-00654-z","volume":"36","author":"M Klietz","year":"2019","unstructured":"Klietz M, Greten S, Wegner F, H\u00f6glinger GU (2019) Safety and tolerability of pharmacotherapies for Parkinson\u2019s disease in geriatric patients. Drugs Aging 36(6):511\u2013530. https:\/\/doi.org\/10.1007\/s40266-019-00654-z","journal-title":"Drugs Aging"},{"key":"3255_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020449","author":"M Klietz","year":"2020","unstructured":"Klietz M, Berndt JM, Wegner F, Schneider N, H\u00f6glinger GU, Eggers C, Stiel S (2020) Consensus-based recommendations for advance directives of people with Parkinson\u2019s disease in regard to typical complications by German movement disorder specialists. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9020449","journal-title":"J Clin Med"},{"key":"3255_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.parkreldis.2017.01.008","volume":"37","author":"BM Kluger","year":"2017","unstructured":"Kluger BM, Fox S, Timmons S, Katz M, Galifianakis NB, Subramanian I, Carter JH, Johnson MJ, Richfield EW, Bekelman D, Kutner JS, Miyasaki J (2017) Palliative care and Parkinson\u2019s disease: meeting summary and recommendations for clinical research. Parkinsonism Relat Disord 37:19\u201326. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.01.008","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"3255_CR48","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00702-025-02911-5","volume":"133","author":"T Koeglsperger","year":"2026","unstructured":"Koeglsperger T, Berberovic E, Dresel C, Haferkamp S, Kassubek J, M\u00fcller R, Oehlwein C, Paus S, Urban PP (2026) Real-world experience with continuous subcutaneous foslevodopa\/foscarbidopa infusion: insights and recommendations. J Neural Transm (Vienna) 133(2):347\u2013359. https:\/\/doi.org\/10.1007\/s00702-025-02911-5","journal-title":"J Neural Transm (Vienna)"},{"issue":"5","key":"3255_CR49","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40273-021-01011-y","volume":"39","author":"C Kruse","year":"2021","unstructured":"Kruse C, Kretschmer S, Lipinski A, Verheyen M, Mengel D, Balzer-Geldsetzer M, Lorenzl S, Richinger C, Schmotz C, T\u00f6nges L, Woitalla D, Klebe S, Schrag A, Dodel R (2021) Resource utilization of patients with Parkinson\u2019s disease in the late stages of the disease in Germany: data from the CLaSP study. Pharmacoeconomics 39(5):601\u2013615. https:\/\/doi.org\/10.1007\/s40273-021-01011-y","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"3255_CR50","doi-asserted-by":"publisher","first-page":"770","DOI":"10.4103\/ijpsym.ijpsym_111_17","volume":"39","author":"M Kumar","year":"2017","unstructured":"Kumar M, Chavan BS, Sidana A, Das S (2017) Efficacy and tolerability of clozapine versus quetiapine in treatment-resistant schizophrenia. Indian J Psychol Med 39(6):770\u2013776. https:\/\/doi.org\/10.4103\/ijpsym.ijpsym_111_17","journal-title":"Indian J Psychol Med"},{"key":"3255_CR51","doi-asserted-by":"publisher","first-page":"130","DOI":"10.18565\/urology.2025.5.130-136","volume":"5","author":"IV Kuzmin","year":"2025","unstructured":"Kuzmin IV (2025) [Pharmacological treatment of overactive bladder: the potential of anticholinergic therapy]. Urologiia 5:130\u2013136","journal-title":"Urologiia"},{"issue":"Suppl 3","key":"3255_CR52","doi-asserted-by":"publisher","first-page":"Iii28","DOI":"10.1007\/pl00007823","volume":"248","author":"S Kuzuhara","year":"2001","unstructured":"Kuzuhara S (2001) Drug-induced psychotic symptoms in Parkinson\u2019s disease. Problems, management and dilemma. J Neurol 248(Suppl 3):Iii28-31. https:\/\/doi.org\/10.1007\/pl00007823","journal-title":"J Neurol"},{"key":"3255_CR53","doi-asserted-by":"publisher","first-page":"4260501","DOI":"10.1155\/2020\/4260501","volume":"2020","author":"B Labeit","year":"2020","unstructured":"Labeit B, Claus I, Muhle P, Suntrup-Krueger S, Dziewas R, Warnecke T (2020) Effect of Intestinal Levodopa-Carbidopa Infusion on Pharyngeal Dysphagia: Results from a Retrospective Pilot Study in Patients with Parkinson\u2019s Disease. Parkinsons Dis 2020:4260501. https:\/\/doi.org\/10.1155\/2020\/4260501","journal-title":"Parkinsons Dis"},{"issue":"8","key":"3255_CR54","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1586\/14737175.8.8.1181","volume":"8","author":"S Lalli","year":"2008","unstructured":"Lalli S, Albanese A (2008) Rivastigmine in Parkinson\u2019s disease dementia. Expert Rev Neurother 8(8):1181\u20131188. https:\/\/doi.org\/10.1586\/14737175.8.8.1181","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"3255_CR55","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/ene.15734","volume":"30","author":"V Leta","year":"2023","unstructured":"Leta V, Klingelhoefer L, Longardner K, Campagnolo M, Levent H, Aureli F, Metta V, Bhidayasiri R, Chung-Faye G, Falup-Pecurariu C, Stocchi F, Jenner P, Warnecke T, Ray Chaudhuri K (2023) Gastrointestinal barriers to levodopa transport and absorption in Parkinson\u2019s disease. Eur J Neurol 30(5):1465\u20131480. https:\/\/doi.org\/10.1111\/ene.15734","journal-title":"Eur J Neurol"},{"key":"3255_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/biom13050829","author":"MM Lewis","year":"2023","unstructured":"Lewis MM, Van Scoy LJ, De Jesus S, Hakun JG, Eslinger PJ, Fernandez-Mendoza J, Kong L, Yang Y, Snyder BL, Loktionova N, Duvvuri S, Gray DL, Huang X, Mailman RB (2023) Dopamine D(1) agonists: first potential treatment for late-stage Parkinson\u2019s disease. Biomolecules. https:\/\/doi.org\/10.3390\/biom13050829","journal-title":"Biomolecules"},{"key":"3255_CR57","doi-asserted-by":"publisher","first-page":"4047392","DOI":"10.1155\/2017\/4047392","volume":"2017","author":"MR Luquin","year":"2017","unstructured":"Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES (2017) Consensus on the definition of advanced Parkinson\u2019s disease: a neurologists-based delphi study (CEPA Study). Parkinsons Dis 2017:4047392. https:\/\/doi.org\/10.1155\/2017\/4047392","journal-title":"Parkinsons Dis"},{"issue":"1\u20132","key":"3255_CR58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3238\/arztebl.m2022.0377","volume":"120","author":"NK Mann","year":"2023","unstructured":"Mann NK, Mathes T, S\u00f6nnichsen A, Pieper D, Klager E, Moussa M, Th\u00fcrmann PA (2023) Potentially inadequate medications in the elderly: PRISCUS 2.0. Dtsch Arztebl Int 120(1\u20132):3\u201310. https:\/\/doi.org\/10.3238\/arztebl.m2022.0377","journal-title":"Dtsch Arztebl Int"},{"issue":"1\u20133","key":"3255_CR59","first-page":"46","volume":"19","author":"Z Mansuri","year":"2022","unstructured":"Mansuri Z, Reddy A, Vadukapuram R, Trivedi C, Amara A (2022) Pimavanserin in the treatment of Parkinson\u2019s disease psychosis: meta-analysis and meta-regression of randomized clinical trials. Innov Clin Neurosci 19(1\u20133):46\u201351","journal-title":"Innov Clin Neurosci"},{"issue":"5","key":"3255_CR60","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11096-015-0094-3","volume":"37","author":"AD Masman","year":"2015","unstructured":"Masman AD, van Dijk M, Tibboel D, Baar FP, Math\u00f4t RA (2015) Medication use during end-of-life care in a palliative care centre. Int J Clin Pharm 37(5):767\u2013775. https:\/\/doi.org\/10.1007\/s11096-015-0094-3","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"3255_CR61","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/practneurol-2016-001515","volume":"17","author":"AJ McGeachan","year":"2017","unstructured":"McGeachan AJ, McDermott CJ (2017) Management of oral secretions in neurological disease. Pract Neurol 17(2):96\u2013103. https:\/\/doi.org\/10.1136\/practneurol-2016-001515","journal-title":"Pract Neurol"},{"issue":"3","key":"3255_CR62","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.parkreldis.2012.11.017","volume":"19","author":"A Melo","year":"2013","unstructured":"Melo A, Monteiro L (2013) Swallowing improvement after levodopa treatment in idiopathic Parkinson\u2019s disease: lack of evidence. Parkinsonism Relat Disord 19(3):279\u2013281. https:\/\/doi.org\/10.1016\/j.parkreldis.2012.11.017","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"3255_CR63","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/01.wnf.0000236769.31279.19","volume":"29","author":"D Merims","year":"2006","unstructured":"Merims D, Balas M, Peretz C, Shabtai H, Giladi N (2006) Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson\u2019s disease psychosis. Clin Neuropharmacol 29(6):331\u2013337. https:\/\/doi.org\/10.1097\/01.wnf.0000236769.31279.19","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"3255_CR64","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/mds.28196","volume":"35","author":"TA Mestre","year":"2020","unstructured":"Mestre TA, Freitas E, Basndwah A, Lopez MR, de Oliveira LM, Al-Shorafat DM, Zhang T, Lui JP, Grimes D, Fox SH (2020) Glycopyrrolate improves disability from sialorrhea in Parkinson\u2019s disease: a 12-week controlled trial. Mov Disord 35(12):2319\u20132323. https:\/\/doi.org\/10.1002\/mds.28196","journal-title":"Mov Disord"},{"key":"3255_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13112704","author":"JP Mota Telles","year":"2025","unstructured":"Mota Telles JP, Labello JH, Camargo L, Pastora-Sesin C, Gianloren\u00e7o AC, Fregni F (2025) Non-motor symptoms as markers of disease severity in Parkinson\u2019s disease: associations between constipation, depression, REM sleep behavior disorder, and motor impairment. Biomedicines (Basel). https:\/\/doi.org\/10.3390\/biomedicines13112704","journal-title":"Biomedicines (Basel)"},{"issue":"1","key":"3255_CR66","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/21681805.2021.1990994","volume":"56","author":"M Moussa","year":"2022","unstructured":"Moussa M, Chakra MA, Dabboucy B, Fares Y, Dellis A, Papatsoris A (2022) The safety and effectiveness of mirabegron in Parkinson\u2019s disease patients with overactive bladder: a randomized controlled trial. Scand J Urol 56(1):66\u201372. https:\/\/doi.org\/10.1080\/21681805.2021.1990994","journal-title":"Scand J Urol"},{"key":"3255_CR67","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajp.2018.03.008","volume":"33","author":"SSR Mukku","year":"2018","unstructured":"Mukku SSR, Sivakumar PT, Varghese M (2018) Clozapine use in geriatric patients- challenges. Asian J Psychiatr 33:63\u201367. https:\/\/doi.org\/10.1016\/j.ajp.2018.03.008","journal-title":"Asian J Psychiatr"},{"issue":"9","key":"3255_CR68","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1136\/gutjnl-2016-311835","volume":"66","author":"AD Nelson","year":"2017","unstructured":"Nelson AD, Camilleri M, Chirapongsathorn S, Vijayvargiya P, Valentin N, Shin A, Erwin PJ, Wang Z, Murad MH (2017) Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis. Gut 66(9):1611\u20131622. https:\/\/doi.org\/10.1136\/gutjnl-2016-311835","journal-title":"Gut"},{"key":"3255_CR69","volume-title":"Parkinson\u2019s disease in adults: diagnosis and management. No. 71","author":"NICE","year":"2017","unstructured":"NICE (2017a) Parkinson\u2019s disease in adults: diagnosis and management. No. 71. National Institute for Health and Care Excellence, London"},{"key":"3255_CR70","volume-title":"Parkinson\u2019s disease in adults: diagnosis and management, Parkinson\u2019s disease in adults: diagnosis and management","author":"NICE","year":"2017","unstructured":"NICE (2017b) Parkinson\u2019s disease in adults: diagnosis and management, Parkinson\u2019s disease in adults: diagnosis and management. National Institute for Health and Care Excellence NICE, London"},{"issue":"4","key":"3255_CR71","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40262-013-0038-9","volume":"52","author":"M Noetzli","year":"2013","unstructured":"Noetzli M, Eap CB (2013) Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer\u2019s disease. Clin Pharmacokinet 52(4):225\u2013241. https:\/\/doi.org\/10.1007\/s40262-013-0038-9","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"3255_CR72","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1177\/1756283x17734809","volume":"10","author":"A Omer","year":"2017","unstructured":"Omer A, Quigley EMM (2017) An update on prucalopride in the treatment of chronic constipation. Ther Adv Gastroenterol 10(11):877\u2013887. https:\/\/doi.org\/10.1177\/1756283x17734809","journal-title":"Ther Adv Gastroenterol"},{"issue":"3","key":"3255_CR73","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41582-023-00918-8","volume":"20","author":"J Pagonabarraga","year":"2024","unstructured":"Pagonabarraga J, Bejr-Kasem H, Martinez-Horta S, Kulisevsky J (2024) Parkinson disease psychosis: from phenomenology to neurobiological mechanisms. Nat Rev Neurol 20(3):135\u2013150. https:\/\/doi.org\/10.1038\/s41582-023-00918-8","journal-title":"Nat Rev Neurol"},{"key":"3255_CR74","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/j.1532-5415.2012.03923.x","volume":"60","author":"Panel T","year":"2012","unstructured":"Panel T (2012) American Geriatrics Society updated beers criteria for potentially inappropriate medication use in old adults. J Am Geriatr Soc 60:616\u2013631. https:\/\/doi.org\/10.1111\/j.1532-5415.2012.03923.x","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"3255_CR75","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/17474124.2020.1769475","volume":"14","author":"B Patel","year":"2020","unstructured":"Patel B, Legacy J, Hegland KW, Okun MS, Herndon NE (2020) A comprehensive review of the diagnosis and treatment of Parkinson\u2019s disease dysphagia and aspiration. Expert Rev Gastroenterol Hepatol 14(6):411\u2013424. https:\/\/doi.org\/10.1080\/17474124.2020.1769475","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"3255_CR76","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12012-010-9088-5","volume":"10","author":"B Paulison","year":"2010","unstructured":"Paulison B, L\u00e9os CL (2010) Potential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literature. Cardiovasc Toxicol 10(4):306\u2013310. https:\/\/doi.org\/10.1007\/s12012-010-9088-5","journal-title":"Cardiovasc Toxicol"},{"key":"3255_CR126","doi-asserted-by":"publisher","unstructured":"Pazan F, Wehling M (2024) Die FORTA (Fit fOR The Aged) Liste. Die Innere Medizin 65(1):3\u20138. https:\/\/doi.org\/10.1007\/s00108-023-01629-4","DOI":"10.1007\/s00108-023-01629-4"},{"issue":"2","key":"3255_CR77","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/ana.10639","volume":"54","author":"EK Perry","year":"2003","unstructured":"Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH (2003) Increased Alzheimer pathology in Parkinson\u2019s disease related to antimuscarinic drugs. Ann Neurol 54(2):235\u2013238. https:\/\/doi.org\/10.1002\/ana.10639","journal-title":"Ann Neurol"},{"issue":"Pt A","key":"3255_CR78","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.toxicon.2015.08.014","volume":"107","author":"M Petracca","year":"2015","unstructured":"Petracca M, Guidubaldi A, Ricciardi L, Ialongo T, Del Grande A, Mulas D, Di Stasio E, Bentivoglio AR (2015) Botulinum toxin A and B in sialorrhea: long-term data and literature overview. Toxicon 107(Pt A):129\u2013140. https:\/\/doi.org\/10.1016\/j.toxicon.2015.08.014","journal-title":"Toxicon"},{"key":"3255_CR79","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2025.10421","author":"E Pinioti","year":"2025","unstructured":"Pinioti E, Glarou E, Lappas AS, Fober I, Helfer B, Siafis S, Christodoulou N, Nikolakopoulou A, Leucht S, Samara M (2025) Examining the safety profile of clozapine versus other antipsychotics: systematic review and meta-analysis. Br J Psychiatry. https:\/\/doi.org\/10.1192\/bjp.2025.10421","journal-title":"Br J Psychiatry"},{"key":"3255_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101569","volume":"62","author":"W Pirker","year":"2026","unstructured":"Pirker W, Ferreira JJ, Rascol O, Poewe W (2026) Management of Parkinson\u2019s disease psychosis-a European perspective. Lancet Reg Health Eur 62:101569. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101569","journal-title":"Lancet Reg Health Eur"},{"key":"3255_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3:17013. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Primers"},{"key":"3255_CR82","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6762528","author":"AA Poirier","year":"2016","unstructured":"Poirier AA, Aub\u00e9 B, C\u00f4t\u00e9 M, Morin N, Di Paolo T, Soulet D (2016) Gastrointestinal dysfunctions in Parkinson\u2019s disease: symptoms and treatments. Parkinsons Dis. https:\/\/doi.org\/10.1155\/2016\/6762528","journal-title":"Parkinsons Dis"},{"key":"3255_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10030516","author":"S Polychronis","year":"2022","unstructured":"Polychronis S, Nasios G, Dardiotis E, Messinis L, Pagano G (2022) Pathophysiology and symptomatology of drooling in Parkinson\u2019s disease. Healthcare (Basel). https:\/\/doi.org\/10.3390\/healthcare10030516","journal-title":"Healthcare (Basel)"},{"issue":"12","key":"3255_CR84","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"key":"3255_CR85","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003771","author":"N Preechakawin","year":"2025","unstructured":"Preechakawin N, Maneerattanaporn M, Geeratragool T, Srivanitchapoom P, Pitakpatapee Y, Leelakusolvong S (2025) Role of prucalopride in the treatment of chronic constipation in Parkinson\u2019s disease: a randomized controlled trial. Am J Gastroenterol. https:\/\/doi.org\/10.14309\/ajg.0000000000003771","journal-title":"Am J Gastroenterol"},{"key":"3255_CR86","doi-asserted-by":"publisher","first-page":"4483517","DOI":"10.1155\/2023\/4483517","volume":"2023","author":"J Read","year":"2023","unstructured":"Read J, Cable S, Bartl G, L\u00f6fqvist C, Iwarsson S, Schrag A (2023) The Lived Experience of Caregiving and Perception of Service Provision among Family-Caregivers of People with Late-Stage Parkinson\u2019s: A Qualitative Study. Parkinsons Dis 2023:4483517. https:\/\/doi.org\/10.1155\/2023\/4483517","journal-title":"Parkinsons Dis"},{"issue":"7","key":"3255_CR87","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00228-015-1860-9","volume":"71","author":"A Renom-Guiteras","year":"2015","unstructured":"Renom-Guiteras A, Meyer G, Th\u00fcrmann PA (2015) The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol 71(7):861\u2013875. https:\/\/doi.org\/10.1007\/s00228-015-1860-9","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3255_CR88","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00702-025-02893-4","volume":"132","author":"P Riederer","year":"2025","unstructured":"Riederer P, Strobel S, Nagatsu T, Watanabe H, Chen X, L\u00f6schmann PA, Sian-Hulsmann J, Jost WH, M\u00fcller T, Dijkstra JM, Monoranu CM (2025) Levodopa treatment: impacts and mechanisms throughout Parkinson\u2019s disease progression. J Neural Transm (Vienna) 132(6):743\u2013779. https:\/\/doi.org\/10.1007\/s00702-025-02893-4","journal-title":"J Neural Transm (Vienna)"},{"key":"3255_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105394","volume":"112","author":"D Rinaldi","year":"2023","unstructured":"Rinaldi D, Galli S, Fanciulli A, Pontieri FE (2023) Levodopa\/carbidopa intestinal gel via percutaneous endoscopic transgastric jejunostomy in advanced Parkinson\u2019s disease: hitting two birds with one stone? Parkinsonism Relat Disord 112:105394. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105394","journal-title":"Parkinsonism Relat Disord"},{"key":"3255_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9050581","author":"H Rodr\u00edguez-Ramallo","year":"2021","unstructured":"Rodr\u00edguez-Ramallo H, B\u00e1ez-Guti\u00e9rrez N, Prado-Mel E, Alfaro-Lara ER, Santos-Ramos B, S\u00e1nchez-Fidalgo S (2021) Association between anticholinergic burden and constipation: a systematic review. Healthcare (Basel). https:\/\/doi.org\/10.3390\/healthcare9050581","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"3255_CR91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3233\/jpd-171181","volume":"8","author":"K Rosqvist","year":"2018","unstructured":"Rosqvist K, Horne M, Hagell P, Iwarsson S, Nilsson MH, Odin P (2018) Levodopa effect and motor function in late stage Parkinson\u2019s disease. J Parkinsons Dis 8(1):59\u201370. https:\/\/doi.org\/10.3233\/jpd-171181","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"3255_CR92","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/mdc3.13186","volume":"8","author":"K Rosqvist","year":"2021","unstructured":"Rosqvist K, Odin P, Lorenzl S, Meissner WG, Bloem BR, Ferreira JJ, Dodel R, Schrag A (2021) Factors associated with health-related quality of life in late-stage Parkinson\u2019s disease. Mov Disord Clin Pract 8(4):563\u2013570. https:\/\/doi.org\/10.1002\/mdc3.13186","journal-title":"Mov Disord Clin Pract"},{"key":"3255_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12010111","author":"K Rosqvist","year":"2022","unstructured":"Rosqvist K, Schrag A, Odin P, The CC (2022) Caregiver burden and quality of life in late stage Parkinson\u2019s disease. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci12010111","journal-title":"Brain Sci"},{"issue":"11","key":"3255_CR94","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00702-025-02994-0","volume":"132","author":"E Roze","year":"2025","unstructured":"Roze E, Rudzinska M, Henriksen T, Pekkonen E, Minar M, Druzdz A, Biering-S\u00f8rensen B, Johansson A, Leu-Semenescu S (2025) Update on sleep disorders in advanced Parkinson\u2019s disease: a narrative review. J Neural Transm (Vienna) 132(11):1705\u20131717. https:\/\/doi.org\/10.1007\/s00702-025-02994-0","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"3255_CR95","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14737175.2021.1883428","volume":"21","author":"K Rukavina","year":"2021","unstructured":"Rukavina K, Batzu L, Boogers A, Abundes-Corona A, Bruno V, Chaudhuri KR (2021) Non-motor complications in late stage Parkinson\u2019s disease: recognition, management and unmet needs. Expert Rev Neurother 21(3):335\u2013352. https:\/\/doi.org\/10.1080\/14737175.2021.1883428","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"3255_CR96","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40265-021-01664-1","volume":"82","author":"D Safarpour","year":"2022","unstructured":"Safarpour D, Sharzehi K, Pfeiffer RF (2022) Gastrointestinal dysfunction in Parkinson\u2019s disease. Drugs 82(2):169\u2013197. https:\/\/doi.org\/10.1007\/s40265-021-01664-1","journal-title":"Drugs"},{"key":"3255_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106982","volume":"124","author":"D Safarpour","year":"2024","unstructured":"Safarpour D, Stover N, Shprecher DR, Hamedani AG, Pfeiffer RF, Parkman HP, Quigley EM, Cloud LJ (2024) Consensus practice recommendations for management of gastrointestinal dysfunction in Parkinson disease. Parkinsonism Relat Disord 124:106982. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106982","journal-title":"Parkinsonism Relat Disord"},{"key":"3255_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120008","volume":"430","author":"A Schindler","year":"2021","unstructured":"Schindler A, Pizzorni N, Cereda E, Cosentino G, Avenali M, Montomoli C, Abbruzzese G, Antonini A, Barbiera F, Benazzo M, Benarroch E, Bertino G, Clav\u00e8 P, Cortelli P, Eleopra R, Ferrari C, Hamdy S, Huckabee ML, Lopiano L, Marchese-Ragona R, Masiero S, Michou E, Occhini A, Pacchetti C, Pfeiffer RF, Restivo DA, Rondanelli M, Ruoppolo G, Sandrini G, Schapira A, Stocchi F, Tolosa E, Valentino F, Zamboni M, Zangaglia R, Zappia M, Tassorelli C, Alfonsi E (2021) Consensus on the treatment of dysphagia in Parkinson\u2019s disease. J Neurol Sci 430:120008. https:\/\/doi.org\/10.1016\/j.jns.2021.120008","journal-title":"J Neurol Sci"},{"key":"3255_CR99","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.parkreldis.2020.05.016","volume":"75","author":"A Schrag","year":"2020","unstructured":"Schrag A, Hommel A, Lorenzl S, Meissner WG, Odin P, Coelho M, Bloem BR, Dodel R (2020) The late stage of Parkinson\u2019s -results of a large multinational study on motor and non-motor complications. Parkinsonism Relat Disord 75:91\u201396. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.05.016","journal-title":"Parkinsonism Relat Disord"},{"key":"3255_CR100","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord 26:S42-80. https:\/\/doi.org\/10.1002\/mds.23884","journal-title":"Mov Disord"},{"issue":"2","key":"3255_CR101","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C (2019) Update on treatments for nonmotor symptoms of Parkinson\u2019s disease-an evidence-based medicine review. Mov Disord 34(2):180\u2013198. https:\/\/doi.org\/10.1002\/mds.27602","journal-title":"Mov Disord"},{"issue":"12","key":"3255_CR102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0310900","volume":"19","author":"SR Shim","year":"2024","unstructured":"Shim SR, Kim JY, Kwon KY, Shin J, Lee Y, Lee SM (2024) Effects of rivastigmine on gait in patients with neurodegenerative disorders: a systematic review and meta-analysis. PLoS ONE 19(12):e0310900. https:\/\/doi.org\/10.1371\/journal.pone.0310900","journal-title":"PLoS ONE"},{"key":"3255_CR103","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/bs.irn.2017.04.012","volume":"134","author":"J S\u0142awek","year":"2017","unstructured":"S\u0142awek J, Madali\u0144ski M (2017) Botulinum toxin therapy for nonmotor aspects of Parkinson\u2019s disease. Int Rev Neurobiol 134:1111\u20131142. https:\/\/doi.org\/10.1016\/bs.irn.2017.04.012","journal-title":"Int Rev Neurobiol"},{"issue":"12","key":"3255_CR104","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1111\/jgs.13858","volume":"63","author":"P Soysal","year":"2015","unstructured":"Soysal P, Isik AT (2015) Asymptomatic bradycardia due to rivastigmine in an elderly adult with Lewy body dementia. J Am Geriatr Soc 63(12):2648\u20132650. https:\/\/doi.org\/10.1111\/jgs.13858","journal-title":"J Am Geriatr Soc"},{"key":"3255_CR105","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.genhosppsych.2024.02.008","volume":"87","author":"M Srisurapanont","year":"2024","unstructured":"Srisurapanont M, Suradom C, Suttajit S, Kongsaengdao S, Maneeton B (2024) Second-generation antipsychotics for Parkinson\u2019s disease psychosis: a systematic review and network meta-analysis. Gen Hosp Psychiatry 87:124\u2013133. https:\/\/doi.org\/10.1016\/j.genhosppsych.2024.02.008","journal-title":"Gen Hosp Psychiatry"},{"issue":"11","key":"3255_CR106","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1097\/jcma.0000000000001146","volume":"87","author":"J Stamenovi\u0107","year":"2024","unstructured":"Stamenovi\u0107 J, \u017divadinovi\u0107 B, \u0110uri\u0107 V (2024) Clinical characteristics and treatment of psychosis in Parkinson\u2019s disease: a narrative review. J Chin Med Assoc 87(11):972\u2013979. https:\/\/doi.org\/10.1097\/jcma.0000000000001146","journal-title":"J Chin Med Assoc"},{"issue":"11","key":"3255_CR107","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1111\/ene.13082","volume":"23","author":"P Stirpe","year":"2016","unstructured":"Stirpe P, Hoffman M, Badiali D, Colosimo C (2016) Constipation: an emerging risk factor for Parkinson\u2019s disease? Eur J Neurol 23(11):1606\u20131613. https:\/\/doi.org\/10.1111\/ene.13082","journal-title":"Eur J Neurol"},{"issue":"3","key":"3255_CR108","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.parkreldis.2012.11.007","volume":"19","author":"JP Sutton","year":"2013","unstructured":"Sutton JP (2013) Dysphagia in Parkinson\u2019s disease is responsive to levodopa. Parkinsonism Relat Disord 19(3):282\u2013284. https:\/\/doi.org\/10.1016\/j.parkreldis.2012.11.007","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"3255_CR109","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2174\/1570159x15666170510143821","volume":"16","author":"N Tambasco","year":"2018","unstructured":"Tambasco N, Romoli M, Calabresi P (2018) Levodopa in Parkinson\u2019s disease: current status and future developments. Curr Neuropharmacol 16(8):1239\u20131252. https:\/\/doi.org\/10.2174\/1570159x15666170510143821","journal-title":"Curr Neuropharmacol"},{"issue":"6","key":"3255_CR110","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/00912700122010528","volume":"41","author":"A Todorova","year":"2001","unstructured":"Todorova A, Vonderheid-Guth B, Dimpfel W (2001) Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 41(6):636\u2013644. https:\/\/doi.org\/10.1177\/00912700122010528","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"3255_CR111","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/s1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W (2021) Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol 20(5):385\u2013397. https:\/\/doi.org\/10.1016\/s1474-4422(21)00030-2","journal-title":"Lancet Neurol"},{"key":"3255_CR112","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.2147\/ndt.s324145","volume":"17","author":"Y Torres-Yaghi","year":"2021","unstructured":"Torres-Yaghi Y, Carwin A, Carolan J, Nakano S, Amjad F, Pagan F (2021) QTc interval prolongation with therapies used to treat patients with Parkinson\u2019s disease psychosis: a narrative review. Neuropsychiatr Dis Treat 17:3791\u20133818. https:\/\/doi.org\/10.2147\/ndt.s324145","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"11","key":"3255_CR113","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41575-020-0339-z","volume":"17","author":"RA Travagli","year":"2020","unstructured":"Travagli RA, Browning KN, Camilleri M (2020) Parkinson disease and the gut: new insights into pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol 17(11):673\u2013685. https:\/\/doi.org\/10.1038\/s41575-020-0339-z","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"3255_CR114","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s13311-013-0236-z","volume":"11","author":"LM Trotti","year":"2014","unstructured":"Trotti LM, Bliwise DL (2014) Treatment of the sleep disorders associated with Parkinson\u2019s disease. Neurotherapeutics 11(1):68\u201377. https:\/\/doi.org\/10.1007\/s13311-013-0236-z","journal-title":"Neurotherapeutics"},{"issue":"2","key":"3255_CR115","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cger.2025.01.001","volume":"41","author":"T Trump","year":"2025","unstructured":"Trump T, Goldman HB (2025) Overactive bladder medications in geriatrics-risks and realities. Clin Geriatr Med 41(2):153\u2013161. https:\/\/doi.org\/10.1016\/j.cger.2025.01.001","journal-title":"Clin Geriatr Med"},{"issue":"1","key":"3255_CR116","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/bmjspcare-2012-000412","volume":"4","author":"RW Walker","year":"2014","unstructured":"Walker RW, Churm D, Dewhurst F, Samuel M, Ramsell A, Lawrie C, Hill J, Threapleton CJ, Wood B, Gray WK (2014) Palliative care in people with idiopathic Parkinson\u2019s disease who die in hospital. BMJ Support Palliat Care 4(1):64\u201367. https:\/\/doi.org\/10.1136\/bmjspcare-2012-000412","journal-title":"BMJ Support Palliat Care"},{"issue":"Pt A","key":"3255_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.gerinurse.2025.103600","volume":"66","author":"S Wang","year":"2025","unstructured":"Wang S, Zhou F, Fang X, Zhang H, Yang W, Xia L, Chen Y, Tan J, Wu Y (2025) Evidence-based summary of the prevention and management of constipation in patients with Parkinson\u2019s disease. Geriatr Nurs 66(Pt A):103600. https:\/\/doi.org\/10.1016\/j.gerinurse.2025.103600","journal-title":"Geriatr Nurs"},{"key":"3255_CR118","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.parkreldis.2016.04.034","volume":"28","author":"T Warnecke","year":"2016","unstructured":"Warnecke T, Suttrup I, Schr\u00f6der JB, Osada N, Oelenberg S, Hamacher C, Suntrup S, Dziewas R (2016) Levodopa responsiveness of dysphagia in advanced Parkinson\u2019s disease and reliability testing of the FEES-Levodopa-test. Parkinsonism Relat Disord 28:100\u2013106. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.04.034","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"3255_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00295-x","volume":"8","author":"T Warnecke","year":"2022","unstructured":"Warnecke T, Sch\u00e4fer KH, Claus I, Del Tredici K, Jost WH (2022) Gastrointestinal involvement in Parkinson\u2019s disease: pathophysiology, diagnosis, and management. NPJ Parkinsons Dis 8(1):31. https:\/\/doi.org\/10.1038\/s41531-022-00295-x","journal-title":"NPJ Parkinsons Dis"},{"issue":"8","key":"3255_CR120","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1177\/1060028017703992","volume":"51","author":"KJ Wilby","year":"2017","unstructured":"Wilby KJ, Johnson EG, Johnson HE, Ensom MHH (2017) Evidence-based review of pharmacotherapy used for Parkinson\u2019s disease psychosis. Ann Pharmacother 51(8):682\u2013695. https:\/\/doi.org\/10.1177\/1060028017703992","journal-title":"Ann Pharmacother"},{"issue":"10","key":"3255_CR121","doi-asserted-by":"publisher","first-page":"778","DOI":"10.31128\/ajgp-05-22-6438","volume":"51","author":"L Williams","year":"2022","unstructured":"Williams L, Qiu J, Waller S, Tsui D, Griffith J, Fung VSC (2022) Challenges in managing late-stage Parkinson\u2019s disease: Practical approaches and pitfalls. Aust J Gen Pract 51(10):778\u2013785. https:\/\/doi.org\/10.31128\/ajgp-05-22-6438","journal-title":"Aust J Gen Pract"},{"issue":"1","key":"3255_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16790-8","volume":"8","author":"QJ Yu","year":"2018","unstructured":"Yu QJ, Yu SY, Zuo LJ, Lian TH, Hu Y, Wang RD, Piao YS, Guo P, Liu L, Jin Z, Li LX, Chan P, Chen SD, Wang XM, Zhang W (2018) Parkinson disease with constipation: clinical features and relevant factors. Sci Rep 8(1):567. https:\/\/doi.org\/10.1038\/s41598-017-16790-8","journal-title":"Sci Rep"},{"issue":"6","key":"3255_CR123","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.639","volume":"7","author":"M Yuan","year":"2017","unstructured":"Yuan M, Sperry L, Malhado-Chang N, Duffy A, Wheelock V, Farias S, O\u2019Connor K, Olichney J, Shahlaie K, Zhang L (2017) Atypical antipsychotic therapy in Parkinson\u2019s disease psychosis: a retrospective study. Brain Behav 7(6):e00639. https:\/\/doi.org\/10.1002\/brb3.639","journal-title":"Brain Behav"},{"key":"3255_CR124","doi-asserted-by":"publisher","unstructured":"Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D, Brunetti G, Pacchetti C (2007) Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 22(9):1239\u20131244. https:\/\/doi.org\/10.1002\/mds.21243","DOI":"10.1002\/mds.21243"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03255-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03255-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03255-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:51:10Z","timestamp":1787323870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03255-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":125,"alternative-id":["3255"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03255-4","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"3 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol (PMU-EK-2024-0008) was approved by the Ethics Committee of Paracelsus Medical University Salzburg in August 2024. In the Tyrolean region, an additional ethical review was performed by the Tirol Kliniken Befragungskommission in April 2025. Our study did not include any intervention applied to a human subject. We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}